Carlo Alfieri
LightNews LightNews
carloalfieri.bsky.social
Carlo Alfieri
@carloalfieri.bsky.social
2 followers 18 following 3 posts
Nephrologist & kidney transplant physician. Associate Professor (University of Milan). Research: CKD progression, diabetes, transplantation, CKD-MBD, onconephrology.
Posts Replies Media Videos
carloalfieri.bsky.social
Kidney stones: could SGLT2 inhibitors help reduce risk? New comprehensive review.
journals.aboutscience.eu/index.php/gc...

International submissions welcome!

#Nephrolithiasis #SGLT2i
@aboutscience.bsky.social
SGLT2 inhibitors in the prevention of nephrolithiasis: a comprehensive review | Giornale di Clinica Nefrologica e Dialisi
journals.aboutscience.eu
December 28, 2025 at 9:49 AM
carloalfieri.bsky.social
Translation and applicability of an Italian version of the Uremic Pruritus in Dialysis Patients (UP-Dial) questionnaire

journals.aboutscience.eu/index.php/gc...

International submissions welcome! #CKDaP

#Hemodialysis #PROs #pruritus
@aboutscience.bsky.social
Translation and applicability of an Italian version of the Uremic Pruritus in Dialysis Patients (UP-Dial) questionnaire | Giornale di Clinica Nefrologica e Dialisi
journals.aboutscience.eu
December 28, 2025 at 9:48 AM
carloalfieri.bsky.social
Beyond tolvaptan, what’s next for ADPKD? New review in GCND (Giornale di Clinica Nefrologica e Dialisi) on SGLT2 inhibitors in PKD.
International submission to the journal are welcome !!!

journals.aboutscience.eu/index.php/gc... #ADPKD #SGLT2i @aboutscience.bsky.social
SGLT2 inhibitors in polycystic kidney disease (PKD): current evidence and future perspectives | Giornale di Clinica Nefrologica e Dialisi
journals.aboutscience.eu
December 28, 2025 at 9:01 AM